Cardinal Health (NYSE:CAH) Price Target Raised to $260.00

Cardinal Health (NYSE:CAH) had its target price lifted by analysts at Evercore ISI from $250.00 to $260.00 in a research note issued to investors on Friday,MarketScreener reports. Evercore ISI’s price target would suggest a potential upside of 14.61% from the stock’s current price.

A number of other research firms also recently weighed in on CAH. UBS Group set a $260.00 price target on Cardinal Health and gave the stock a “buy” rating in a research note on Friday. Jefferies Financial Group boosted their target price on shares of Cardinal Health from $220.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft raised their price target on shares of Cardinal Health from $195.00 to $208.00 and gave the company a “hold” rating in a report on Tuesday, November 18th. Leerink Partners boosted their price objective on shares of Cardinal Health from $240.00 to $268.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Argus increased their price target on Cardinal Health from $211.00 to $232.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Fifteen research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $241.27.

Cardinal Health Price Performance

CAH stock opened at $226.85 on Friday. The firm has a market capitalization of $53.90 billion, a P/E ratio of 32.64, a P/E/G ratio of 1.51 and a beta of 0.64. Cardinal Health has a 52-week low of $120.72 and a 52-week high of $230.81. The company’s 50 day simple moving average is $206.92 and its 200-day simple moving average is $179.97.

Cardinal Health (NYSE:CAH) last posted its quarterly earnings data on Thursday, February 5th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.31 by $0.32. The firm had revenue of $65.63 billion for the quarter, compared to analysts’ expectations of $64.88 billion. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.93 EPS. Sell-side analysts predict that Cardinal Health will post 7.95 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Aventura Private Wealth LLC purchased a new stake in Cardinal Health during the fourth quarter valued at about $25,000. SJS Investment Consulting Inc. raised its stake in shares of Cardinal Health by 1,363.6% in the third quarter. SJS Investment Consulting Inc. now owns 161 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in shares of Cardinal Health during the fourth quarter valued at $34,000. Atlantic Edge Private Wealth Management LLC increased its holdings in Cardinal Health by 75.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 175 shares of the company’s stock worth $29,000 after buying an additional 75 shares in the last quarter. Finally, Barnes Dennig Private Wealth Management LLC increased its holdings in Cardinal Health by 38.7% in the 4th quarter. Barnes Dennig Private Wealth Management LLC now owns 190 shares of the company’s stock worth $39,000 after buying an additional 53 shares in the last quarter. 87.17% of the stock is owned by institutional investors.

Trending Headlines about Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
• Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
• Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
• Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
• Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
• Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

Cardinal Health Company Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.